Introduction
Hormonal differences related to sex have been associated with the risk of developing multiple sclerosis (MS). In addition, hormonal changes during life such as pregnancy and postpartum can affect MS onset and progression. Puberty is a time of dramatic hormonal changes. Its effects on MS in general have been scarcely studied, in part, not only due to the rarity of MS onset in childhood and the limited clinical milestones defining various stages of puberty but also due to the challenges related to extensive and dynamic biological changes during this phase of life.
How is puberty defined
Puberty is a process encompassing several years and marks the end of childhood. Physiological puberty starts between 8 and 12 years of age in girls and 9 and 14 years of age in boys. 1 Pubertal changes include the development of sex organs, the onset of secondary sexual characteristics, and achievement of fertility while body composition is also altered and rate of growth peaks. The changes are under the controls of the hypothalamic-pituitary-gonadal axis and are regulated by complex excitatory and inhibitory factors. Active inhibition of gonadotropin releasing hormone (GnRH) starts from age of 6 months in boys and 3-4 years in girls and persists throughout childhood. Puberty is initiated by a sustained increase in the pulsatile release of GnRH and is completed within 3-4 years. GnRH stimulates pituitary hormones luteinizing hormone (LH) and follicle-stimulating hormone (FSH) which in turn act on gonads. For girls, menarche (i.e. first menstrual cycles) marks the end of puberty. For boys, testicular enlargement is followed by increased growth velocity (reviewed in Abreu and Kaiser 1 ).
Modifiers of age of puberty
Several nutritional, environmental, and genetic factors control and regulate puberty initiation, that is, pulsatile GnRH secretion. 1 Racial and ethnic differences are known, such as menarche occurs earlier in non-Hispanic Black girls versus White girls. Data suggest that the variability of age of puberty is 50%-80% genetically determined and includes the kisspeptin system, tachykinins and their receptors, and makorin ring finger protein 3 among others. Age of puberty is also modulated by metabolic and nutritional factors including exercise. For example, peripheral hormones such as insulin, leptin, and ghrelin signal to the reproductive axis and modulate age of puberty (reviewed in Abreu and Kaiser 1 ).
Challenges studying puberty and MS
Pediatricians often use Tanner staging to define the phase of puberty in boys and girls. 2 This staging includes five phases for changes in pubic hair, breast, and genital development. The first clinical evidence of puberty initiation is the thelarche (breast development) in girls and testicular enlargement in boys. These rely on clinical examination or self-description and as such make difficult the identification of the beginning of puberty in cohort studies. The
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development of axillary and pubic hair (pubarche) is not a good marker of puberty onset as it is dependent the increase in the adrenal androgen production. There is no single well-defined clinical milestone except for menarche that marks the end of puberty for girls. For boys, testicular enlargement is followed by growth acceleration and spermarche.
Defining pubertal stage requires a clinical examination by a pediatrician (Tanner stage) or self report, which is much less accurate. Alternatively, capturing time of growth spurt (based on longitudinal capture of height/weight) may also be helpful. For more precise studies, longitudinal blood samples taken in the morning would clarify sex hormone status, but are not practical. As a result, it remains challenging to separate age from puberty-related changes.
Puberty and immune response
The impact of pubertal changes in the immune response has mostly been studied in animals. The immune response is skewed toward a Th2 bias in the early postnatal period, followed by an age-related Th1 (IFN-γ) increase. 3 Testosterone decreases IL-6 and leptin production while it increases C-reactive protein (CRP), TNFa, adiponectin, and ghrelin. Estradiol also decreases IL-6 production and increases TNFa, but in contrast with testosterone, stimulates leptin while decreasing adiponectin and ghrelin. Sex hormone binding globulin (SHBG) has an opposite effect on IL-6, CRP, and TNFa compared to testosterone and estradiol.
Puberty and animal models of MS Susceptibility to experimental autoimmune encephalomyelitis (EAE) in mice peaks during puberty. 4 EAE is very difficult to induce before then. Female mice that have transitioned through puberty are more susceptible to EAE than age-matched, pre-pubertal mice in a model using ovariectomy at 4 weeks, but disease severity and number of infiltrating leukocytes were similar. 5 Spleen and lymph node cells proliferated more robustly in post-pubertal mice after stimulation with a proteolipid protein (PLP) peptide, and antigen presenting cells (APC) were less able to prime autoreactive CD4+ T cells in pre-pubertal mice probably explaining the decreased EAE susceptibility.
Puberty and MS onset
In a large US database of several hundred pediatric MS cases, there were two peaks of disease onset centered, respectively, around age of 4 and 15 years. 6 The sex ratio of these cases was one to one under age of 9 years and started to switch to a clear female predominance starting at 9 years of age, suggesting a strong effect of sex hormones on the risk to develop the disease during childhood and adolescence.
In a retrospective study of the influence of puberty in 70 girls with MS onset before the age of 18, three groups were defined based on time of MS onset relative to time of menarche: pre-menarche, perimenarche (from 6 months pre-menarche to 6 months post-menarche), and post-menarche. 7 Age of menarche was similar in the three groups suggesting MS may not influence age of menarche. Of interest, MS onset peaked 2 years after menarche suggesting hormonal changes related to puberty may modulate age of MS onset taking into consideration that hormonal changes continue during the immediate postmenarche phase and that the disease is often preceded by a clinically silent phase. 7 The relationship between menarche and risk of relapse is reviewed below. In another pediatric study of 254 cases and 420 controls, earlier age at sexual maturity, particularly in combination with obesity, was associated with earlier age of pediatric MS onset. 8 In adult-onset MS, an increased risk of MS has been reported with an earlier age of menarche. 9 This study included 5493 MS cases and 1759 spousal controls with age of puberty information from the Canadian Collaborative Project on Genetic Susceptibility to MS. There were no differences in age of puberty between male cases and controls. In women, an earlier age at menarche increased MS risk: average age of puberty was 12.4 (cases) and 12.6 (controls) years (p = 0.00017). The relative risk decreased by 0.9 per year increase in the age of puberty. There was no effect of puberty age on age of MS onset in either sex. In contrast, a 1-year increase for age at symptom onset was described in another study for each year increase in the menarche age suggesting a relationship between the two. 10 The effect of puberty on MS susceptibility is challenging to tease out from other risk factors such as obesity and is best studied in pediatric MS in order to obtain more precise information related to various stages of puberty. A distinct clinical, cerebral spinal fluid (CSF) and magnetic resonance imaging (MRI) profile has also been identified in patients younger than 11 years, and it is unclear how it relates to puberty. 11, 12 Puberty and MS course Disease phenotype may be altered by age of MS onset. Cognitive/cerebral symptoms might be more common in younger patients (pre-pubertal onset). 7 In a larger cohort, age of MS onset also modified disease phenotype of the clinical presentation. 6 Younger patients (before 11 years) were more likely to have encephalopathic and coordination symptoms at disease onset, whereas older patients were more likely to have cord events.
In addition to a possible influence of age of onset on MS phenotype, puberty may affect the risk of relapses in children with the disease. 7 An increase in the incidence rate ratio for relapses during the peri-menarche epoch compared to post-menarche has been reported after adjustment for use of disease-modifying therapies while the pre-menarche epoch did not appear different (Table 1) . 7 A similar study in boys used age instead of a specific clinical landmark of puberty and also reported an association between pubertal status at disease onset with relapse rate; 13 however, this study does not separate age from puberty influence.
In children with first demyelinating events including acute disseminated encephalomyelitis (ADEM), isolated optic neuritis, isolated transverse myelitis, neuromyelitis optica, and MS, a later age of menarche was associated with a decreased risk of subsequent MS diagnosis (HR 0.64). 5 In addition, age of onset may also be associated with first and second relapse recovery as children recovered better than adults. 14 
Conclusion
The aforementioned observations are important to understand from a clinical standpoint when caring for young patients and making treatment decisions based on disease activity. They may also unravel critical biological processes that may be relevant to adult MS and might lead to new therapeutic strategies.
There is a clear change in MS sex ratio related to puberty. Puberty and age at puberty may affect the risk to develop MS. There is a possible association of puberty and disease activity, but it should be confirmed before making strong treatment recommendations. The precise underlying biological processes underlying these observations remain to be defined.
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